Literature DB >> 24583624

Risk factors for hypogammaglobulinemia after allo-SCT.

Y Arai1, K Yamashita1, K Mizugishi1, T Kondo1, T Kitano1, M Hishizawa1, N Kadowaki1, A Takaori-Kondo1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24583624     DOI： 10.1038/bmt.2014.28

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

Review 2.  Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Authors:  Kentaro Minagawa; Motohiro Yamamori; Yoshio Katayama; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

3.  Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Yasuyuki Arai; Kouhei Yamashita; Kiyomi Mizugishi; Tomohiro Watanabe; Soichiro Sakamoto; Toshiyuki Kitano; Tadakazu Kondo; Hiroshi Kawabata; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-19       Impact factor: 5.742

4.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Authors:  Carla Casulo; Jocelyn Maragulia; Andrew D Zelenetz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

5.  Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model.

Authors:  J Gregoire-Gauthier; L Durrieu; A Duval; F Fontaine; M M Dieng; M Bourgey; N Patey-Mariaud de Serre; I Louis; E Haddad
Journal:  Bone Marrow Transplant       Date:  2011-05-16       Impact factor: 5.483

6.  Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group.

Authors:  Y Morishima; Y Morishita; M Tanimoto; R Ohno; H Saito; K Horibe; N Hamajima; K Naito; K Yamada; S Yokomaku
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

7.  Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT.

Authors:  H Frangoul; E Min; W Wang; R Chandrasekhar; C Calder; M Evans; B Manes; K Bruce; V Brown; R Ho; J Domm
Journal:  Bone Marrow Transplant       Date:  2013-05-27       Impact factor: 5.483

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

9.  Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine.

Authors:  K Keven; M Sahin; S Kutlay; S Sengul; S Erturk; S Ersoz; B Erbay
Journal:  Transpl Infect Dis       Date:  2003-12       Impact factor: 2.228

10.  A potential role for B cells in suppressed immune responses in cord blood transplant recipients.

Authors:  B C Beaudette-Zlatanova; P T Le; K L Knight; S Zhang; S Zakrzewski; M Parthasarathy; P J Stiff
Journal:  Bone Marrow Transplant       Date:  2012-06-25       Impact factor: 5.483
View more
  5 in total

1.  Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.

Authors:  Y Arai; T Kondo; T Kitano; M Hishizawa; K Yamashita; N Kadowaki; T Yamamoto; I Yano; K Matsubara; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

2.  Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.

Authors:  Yasuyuki Arai; Tadakazu Kondo; Hirohito Yamazaki; Katsuto Takenaka; Junichi Sugita; Takeshi Kobayashi; Yukiyasu Ozawa; Naoyuki Uchida; Koji Iwato; Naoki Kobayashi; Yoshiyuki Takahashi; Ken Ishiyama; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Takehiko Mori; Takanori Teshima
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

Review 3.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

4.  Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis.

Authors:  Ewa Karakulska-Prystupiuk; Jadwiga Dwilewicz-Trojaczek; Joanna Drozd-Sokołowska; Ewelina Kmin; Marcin Chlebus; Karolina Szczypińska; Piotr Boguradzki; Agnieszka Tomaszewska; Krzysztof Mądry; Jarosław Biliński; Grzegorz Władysław Basak; Wiesław Wiktor Jędrzejczak
Journal:  Ann Hematol       Date:  2021-09-03       Impact factor: 4.030

Review 5.  Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.

Authors:  Akihiro Ohmoto; Shigeo Fuji; Kendall C Shultes; Bipin N Savani; Hermann Einsele
Journal:  Bone Marrow Transplant       Date:  2022-04-19       Impact factor: 5.174
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.